The FDA announced in December 2013 that it is recommending the bedtime dose of Zolpidem (brand name Ambien) be lowered due to the risk of next-morning impairment. In a press release issued in December 2013, the FDA says it recommending the change “because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving.” The FDA is requiring manufacturers of Ambien, Ambien CR, Edluar and Zolpimist to lower the recommended dose “because use of lower doses of Zolpidem will result in lower blood levels in the morning.”